[
  {
    "ts": null,
    "headline": "Is There Still Value In Biogen (BIIB) After The Recent Share Price Recovery",
    "summary": "If you are wondering whether Biogen’s current share price still offers value, or if the recent run has already priced in the good news, this article is for you. Biogen closed at US$185.63, with returns of 1.7% over 7 days, 6.6% over 30 days, 4.4% year to date, and 29.8% over 1 year. However, the 3-year and 5-year returns of 35.9% and 32.2% declines tell a different story for longer term holders. Recent news flow around Biogen has centered on its position in pharmaceuticals and biotech and on...",
    "url": "https://finnhub.io/api/news?id=4c960e76d48aa113a235ec466e094cf761f45e0a0f2a0ceb0ac5117dc829037e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768334828,
      "headline": "Is There Still Value In Biogen (BIIB) After The Recent Share Price Recovery",
      "id": 138096976,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "If you are wondering whether Biogen’s current share price still offers value, or if the recent run has already priced in the good news, this article is for you. Biogen closed at US$185.63, with returns of 1.7% over 7 days, 6.6% over 30 days, 4.4% year to date, and 29.8% over 1 year. However, the 3-year and 5-year returns of 35.9% and 32.2% declines tell a different story for longer term holders. Recent news flow around Biogen has centered on its position in pharmaceuticals and biotech and on...",
      "url": "https://finnhub.io/api/news?id=4c960e76d48aa113a235ec466e094cf761f45e0a0f2a0ceb0ac5117dc829037e"
    }
  },
  {
    "ts": null,
    "headline": "Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight",
    "summary": "The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & Johnson), Litifilimab (Biogen and Royalty Pharma), Ianalumab (Novartis), Cenerimod (Idorsia and Viatris), Rapcabtagene autoleucel (YTB323) (Novartis), KK-4277 (Kyowa Kirin), and others, and better diagnostic tools, which might improve the prognosis of the disease.New York, USA, Jan. 13, 2026 (GLOBE NEW",
    "url": "https://finnhub.io/api/news?id=9018a25a2a4615bbb33eb24bd758fac97e29535b9bd1ad45b8fc6d54ce26dedf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768327200,
      "headline": "Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight",
      "id": 138086644,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & Johnson), Litifilimab (Biogen and Royalty Pharma), Ianalumab (Novartis), Cenerimod (Idorsia and Viatris), Rapcabtagene autoleucel (YTB323) (Novartis), KK-4277 (Kyowa Kirin), and others, and better diagnostic tools, which might improve the prognosis of the disease.New York, USA, Jan. 13, 2026 (GLOBE NEW",
      "url": "https://finnhub.io/api/news?id=9018a25a2a4615bbb33eb24bd758fac97e29535b9bd1ad45b8fc6d54ce26dedf"
    }
  },
  {
    "ts": null,
    "headline": "JPM26: Biotech’s M&A lift, the ‘new’ Biogen and Merck’s $70B target",
    "summary": "Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all approaching crucial trial readouts.",
    "url": "https://finnhub.io/api/news?id=49424a515a66b66db2e1e95fc1496a424f7841a4a1af23c4f4b25a425fd805eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768322700,
      "headline": "JPM26: Biotech’s M&A lift, the ‘new’ Biogen and Merck’s $70B target",
      "id": 138091493,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all approaching crucial trial readouts.",
      "url": "https://finnhub.io/api/news?id=49424a515a66b66db2e1e95fc1496a424f7841a4a1af23c4f4b25a425fd805eb"
    }
  },
  {
    "ts": null,
    "headline": "Biogen CEO Chris Viehbacher on 2026 drug pipeline outlook, rare disease strategy",
    "summary": "Biogen CEO Chris Viehbacher joins 'Squawk Box' to discuss the company's 2026 outlook, drug pipeline, the focus on rare diseases, state of the biotech sector, and more.",
    "url": "https://finnhub.io/api/news?id=10c83f72a00aa2f8a848e14581f2c35367a72c37e5328e3ee08cb5d8effc0e9a",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768293040,
      "headline": "Biogen CEO Chris Viehbacher on 2026 drug pipeline outlook, rare disease strategy",
      "id": 138086133,
      "image": "https://image.cnbcfm.com/api/v1/image/108251658-17683104561768310452-43475015756-1080pnbcnews.jpg?v=1768310455&w=1920&h=1080",
      "related": "BIIB",
      "source": "CNBC",
      "summary": "Biogen CEO Chris Viehbacher joins 'Squawk Box' to discuss the company's 2026 outlook, drug pipeline, the focus on rare diseases, state of the biotech sector, and more.",
      "url": "https://finnhub.io/api/news?id=10c83f72a00aa2f8a848e14581f2c35367a72c37e5328e3ee08cb5d8effc0e9a"
    }
  },
  {
    "ts": null,
    "headline": "Biogen CEO Says New Drugs Offset MS Decline, Eyes 2026 “Transformational Era” at JPMorgan Conference",
    "summary": "Biogen (NASDAQ:BIIB) CEO Chris Viehbacher told investors the company has worked to stabilize its business as its multiple sclerosis (MS) portfolio continues to decline, while building new growth drivers and reshaping its cost structure. Speaking in a JPMorgan session moderated by analyst Chris Schot",
    "url": "https://finnhub.io/api/news?id=272312093141edf82b86750ea0f8fe52dc562e899eb62359961ef5c1791f57a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768291359,
      "headline": "Biogen CEO Says New Drugs Offset MS Decline, Eyes 2026 “Transformational Era” at JPMorgan Conference",
      "id": 138083759,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen (NASDAQ:BIIB) CEO Chris Viehbacher told investors the company has worked to stabilize its business as its multiple sclerosis (MS) portfolio continues to decline, while building new growth drivers and reshaping its cost structure. Speaking in a JPMorgan session moderated by analyst Chris Schot",
      "url": "https://finnhub.io/api/news?id=272312093141edf82b86750ea0f8fe52dc562e899eb62359961ef5c1791f57a4"
    }
  }
]